Pure carbon nanotubes pass first in vivo test

November 27, 2006

HOUSTON, Nov. 27, 2006 -- In the first experiments of their kind, researchers at Rice University and The University of Texas M. D. Anderson Cancer Center have determined that carbon nanotubes injected directly into the bloodstream of research lab animals cause no immediate adverse health effects and circulate for more than one hour before they are removed by the liver.

The findings are from the first in vivo animal study of chemically unmodified carbon nanotubes, a revolutionary nanomaterial that many researchers hope will prove useful in diagnosing and treating disease. The research will appear in this week's online edition of the Proceedings of the National Academy of Sciences.

"We sampled tissues from a dozen organs, and found significant amounts of nanotubes only in the liver," said lead author Bruce Weisman, professor of chemistry. "The liver naturally removes drugs or compounds from the blood, so this is what we expected to find."

The study, which tracked where the nanotubes went within 24 hours of being injected, also revealed trace amounts of nanotubes in the kidneys - another common expulsion route for drugs. There was no evidence that nanotubes remained in other tissues in the body.

Nanotubes are hollow cylinders of pure carbon that measure just one nanometer in diameter - about the same width as a strand of DNA. Nanotubes have unique chemical and optical properties, and they have attracted intense interest from biomedical researchers.

"The early results are promising for anyone interested in using carbon nanotubes in biomedical applications," said co-author Dr. Steven Curley, professor of surgical oncology and chief of gastrointestinal tumor surgery at M. D. Anderson. "We are particularly pleased that the fluorescent effect remains intact in our application, because this makes it easier to see where the nanotubes end up, and it opens the door to some exciting diagnostic and therapeutic applications."

In a ground-breaking 2002 study, Weisman and colleagues at Rice, including the late Professor Richard Smalley, discovered that nanotubes fluoresce, or emit near infrared light. Because near-infrared light passes harmlessly into the body, biomedical researchers are keen to use carbon nanotubes for the noninvasive diagnosis and treatment of diseases such as cancer and atherosclerosis.

In the current study, Weisman, Curley and colleagues injected lab animals with water soluble single-walled carbon nanotubes. The nanotubes, whose biocompatible coating was displaced by proteins in the blood, continued to fluoresce in the animals.

"I still remember how excited we were when we confirmed that the tubes were fluorescing," said Paul Cherukuri, a doctoral degree candidate in Chemistry. The researchers used this fluorescence to track the nanotubes in the blood and image them in tissues under the microscope.

Cherukuri said Smalley initiated several follow-up projects shortly before his passing in 2005 from lymphoma. In one, researchers are working on methods that will allow nanotubes to circulate longer following injection, so that they can be more easily targeted to specific organs. In another, they are tracking the longer-term behavior and effects of nanotubes in research lab animals.

"This research grew out of Smalley's vision, and he followed our progress and offered daily guidance, even from his hospital bed at M.D. Anderson," Cherukuri said. "Up to his very last day, he was simultaneously fighting his own battle with cancer and developing new ways to treat the disease that ultimately took his life. These new results are simply the first fruits of his final contributions in nanohealth research, and there are still more to come."
-end-
CONTACT:

Julie Penne
M. D. Anderson Cancer Center
713-792-0662
jpenne@mdanderson.org

The research was funded by the Alliance for NanoHealth, NASA, Rice University's Center for Biological and Environmental Nanotechnology, the National Science Foundation, the Welch Foundation, and the National Institutes of Health.

Rice University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.